Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer

Şendur, Mehmet; Aksoy, Sercan; Yazıcı, Ozan; Ozdemir, Nuriye; Zengin, Nurullah; Altundag, Kadri
February 2014
Medical Oncology;Feb2014, Vol. 31 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. Ahern, Thomas P.; Pedersen, Lars; Tarp, Maja; Cronin-Fenton, Deirdre P.; Garne, Jens Peter; Silliman, Rebecca A.; Sørensen, Henrik Toft; Lash, Timothy L. // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 19, p1461 

    Background Accumulating evidence suggests that statins affect diseases other than cardiovascular disease, including cancer, and that these effects may depend on the lipid solubility of specific statins. Though many studies have reported an association between statin use and breast cancer...

  • Statins and risk of breast cancer recurrence. Sakellakis, Minas; Akinosoglou, Karolina; Kostaki, Anastasia; Spyropoulou, Despina; Koutras, Angelos // Breast Cancer: Targets & Therapy;Nov2016, Vol. 8, p199 

    Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III...

  • Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer. Forse, Catherine; Yilmaz, Yildiz; Pinnaduwage, Dushanthi; O'Malley, Frances; Mulligan, Anna; Bull, Shelley; Andrulis, Irene // Breast Cancer Research & Treatment;Feb2013, Vol. 137 Issue 3, p709 

    Lymphatic invasion (LVI) is associated with disease recurrence in axillary node-negative (ANN) breast cancer. Using gene expression profiling of 105 ANN tumors, we found that podocalyxin (PODXL) was more highly expressed in tumors with LVI (LVI+) than in those without LVI (LVI−)....

  • Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas. Wen-Hung Kuo; Yao-Yin Chang; Liang-Chuan Lai; Mong-Hsun Tsai; Chuhsing Kate Hsiao; King-Jen Chang; Chuang, Eric Y.; Ju-Seog Lee // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Background: Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and distinct disease etiology. Due to the lack of an effective targeted medicine, treatment options for triple-negative breast cancer are few and recurrence rates are high. Although various...

  • Impact of Vascular Invasion of a Primary Tumor as a Strong Risk Factor for Disease Recurrence in Patients with Node-Positive Breast Cancer. TAKAAKI FUJII; REINA YAJIMA; HIROKI MORITA; TOMOKO HIRAKATA; TAKESHI MIYAMOTO; TOMOMI FUJISAWA; SOICHI TSUTSUMI; YASUHIRO YNAGITA; MISA IIJIMA; HIROYUKI KUWANO // American Surgeon;May2015, Vol. 81 Issue 5, p523 

    The presence of lymph node metastasis is considered to be the most significant indicator of prognosis. However, in some cases with node-positive breast cancer, cancer cell dissemination is localized to the lymphatic systems. It is, therefore, important to develop selection criteria for strong...

  • The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists. JOH, JENNIFER E.; ESPOSITO, NICOLE N.; KILUK, JOHN V.; LARONGA, CHRISTINE; LEE, M. CATHERINE; LOFTUS, LORETTA; SOLIMAN, HATEM; BOUGHEY, JUDY C.; REYNOLDS, CAROL; LAWTON, THOMAS J.; ACS, PETER I.; GORDAN, LUCIO; ACS, GEZA // Oncologist;Nov2011, Vol. 16 Issue 11, p1520 

    Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor-positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores...

  • Clinicopathologic Relevance of Claudin 5 Expression in Breast Cancer. Hitoshi Sugimoto; Makoto Nagahara; Yuan Bae; Tsuyoshi Nakagawa; Toshiaki Ishikawa; Takanobu Sato; Hiroyuki Uetake; Yoshinobu Eishi; Kenichi Sugihara // American Journal of Clinical Pathology;2015, Vol. 143 Issue 4, p540 

    Objectives: Claudins are major adhesion molecules in tight junctions and are strongly expressed in various cancers. We thus investigated the expression of claudin 5, a member of the claudin family, in breast cancer. Methods: A total of 193 patients with breast cancer were identified based on...

  • Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. Murtola, Teemu J.; Visvanathan, Kala; Artama, Miia; Vainio, Harri; Pukkala, Eero // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Recent studies have suggested that statins, an established drug group in the prevention of cardiovascular mortality, could delay or prevent breast cancer recurrence but the effect on disease-specific mortality remains unclear. We evaluated risk of breast cancer death among statin users in a...

  • Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative. Cauley, Jane A.; McTiernan, Anne; Rodabough, Rebecca J.; Lacroix, Andrea; Bauer, Douglas C.; Margolis, Karen L.; Paskett, Electra D.; Vitolins, Mara Z.; Furberg, Curt D.; Chlebowski, Rowan T. // JNCI: Journal of the National Cancer Institute;5/17/2006, Vol. 98 Issue 10, p700 

    Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed conclusions about the relationship between statin use and breast cancer risk. Methods: To investigate associations...

  • Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort. Nickels, Stefan; Vrieling, Alina; Seibold, Petra; Heinz, Judith; Obi, Nadia; Flesch-Janys, Dieter; Chang-Claude, Jenny // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Lipid-lowering drugs are used for the prevention of cardiovascular diseases. Statins are the most commonly used lipid-lowering drugs. Evidence from preclinical and observational studies suggests that statins might improve the prognosis of breast cancer patients. We analyzed data from the German...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics